Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Severe hepatitis caused by cyproterone acetate.

J C Blake1, A M Sawyerr, J S Dooley

  • 1Academic Department of Medicine, Royal Free Hospital School of Medicine, Hampstead, London.

Gut
|May 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp).

ESMO open·2021
Same author

Investigation of hepatitis C in haemophilia including liver biopsy.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

The new clinical curriculum at the royal free hospital school of medicine.

Medical teacher·2014
Same author

Hepatobiliary disease associated with hypereosinophilia: a report of two patients and a review of the literature.

Digestive diseases and sciences·2011
Same author

Two Cases of Thromboembolic Disease Associated with Oral Contraceptives.

British medical journal·2010
Same author

Sediment and pollutant load modelling using an integrated urban drainage modelling toolbox: an application of City Drain.

Water science and technology : a journal of the International Association on Water Pollution Research·2010
Same journal

Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study.

Gut·2026
Same journal

Dysregulated sphingolipid metabolismdrives pancreatic carcinogenesis through plasma membrane Kras enrichment.

Gut·2026
Same journal

USP20 promotes CD8<sup>+</sup> T cell exhaustion and impairs KRAS<sup>G12D</sup> inhibitor efficacy by orchestrating cholesterol metabolism and autophagy in pancreatic cancer.

Gut·2026
Same journal

CTCF-rs705704-SUOX axis is important for the association between hypothyroidism and metabolic dysfunction-associated steatotic liver disease.

Gut·2026
Same journal

<i>Helicobacter pylori</i> infection, treatment and colorectal cancer risk by genetic predisposition: evidence from two randomised trials.

Gut·2026
Same journal

Correction: Sodium+/taurocholate cotransporting polypeptide as target therapy for liver fibrosis.

Gut·2026
See all related articles

Cyproterone acetate, used for prostate cancer, can cause severe liver damage. Regular liver function tests are crucial for patients on high doses, with immediate drug cessation advised if abnormalities arise.

Area of Science:

  • Hepatology
  • Oncology
  • Pharmacology

Background:

  • Cyproterone acetate is a widely used antiandrogen for treating prostate carcinoma.
  • Adverse hepatic reactions to cyproterone acetate are infrequently documented in medical literature.
  • The drug's potential for hepatotoxicity necessitates careful monitoring.

Observation:

  • A case report details severe acute hepatitis in a 71-year-old male patient with prostatic carcinoma receiving cyproterone acetate.
  • This represents the fourth published instance of a significant adverse hepatic event linked to this medication.
  • The patient's presentation underscores the potential for serious liver injury.

Findings:

  • The case substantiates existing, albeit limited, evidence of cyproterone acetate's hepatotoxic potential.

Related Experiment Videos

  • A strong association was observed between cyproterone acetate use and the development of acute hepatitis.
  • The severity of the hepatitis highlights the drug's risk profile.

    • Implications:

    • Mandatory monitoring of liver function tests is recommended for patients on high-dose cyproterone acetate therapy.
    • Prompt discontinuation of the drug is advised upon detection of abnormal liver function test results.
    • This case emphasizes the need for increased vigilance regarding cyproterone acetate-induced liver injury in clinical practice.